This company has been marked as potentially delisted and may not be actively trading. Cogent Biosciences (UMRX) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock UMRX vs. CALT, ZYME, CMRX, CDMO, MENS, SBTX, MBX, RVNC, CKPT, and AVTEShould you be buying Cogent Biosciences stock or one of its competitors? The main competitors of Cogent Biosciences include Calliditas Therapeutics AB (publ) (CALT), Zymeworks (ZYME), Chimerix (CMRX), Avid Bioservices (CDMO), Jyong Biotech (MENS), Silverback Therapeutics (SBTX), MBX Biosciences (MBX), Revance Therapeutics (RVNC), Checkpoint Therapeutics (CKPT), and Aerovate Therapeutics (AVTE). Cogent Biosciences vs. Its Competitors Calliditas Therapeutics AB (publ) Zymeworks Chimerix Avid Bioservices Jyong Biotech Silverback Therapeutics MBX Biosciences Revance Therapeutics Checkpoint Therapeutics Aerovate Therapeutics Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Cogent Biosciences (NASDAQ:UMRX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, media sentiment, profitability, risk, institutional ownership and analyst recommendations. Do institutionals and insiders believe in CALT or UMRX? 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. Comparatively, 26.4% of Cogent Biosciences shares are owned by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are owned by insiders. Comparatively, 31.5% of Cogent Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is CALT or UMRX more profitable? Calliditas Therapeutics AB (publ) has a net margin of -30.18% compared to Cogent Biosciences' net margin of -96.84%. Cogent Biosciences' return on equity of -87.78% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets Calliditas Therapeutics AB (publ)-30.18% -212.04% -27.96% Cogent Biosciences -96.84%-87.78%-52.14% Which has better earnings and valuation, CALT or UMRX? Cogent Biosciences has lower revenue, but higher earnings than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62Cogent Biosciences$22.50M14.31-$31.83M-$1.04-7.29 Does the media refer more to CALT or UMRX? In the previous week, Calliditas Therapeutics AB (publ)'s average media sentiment score of 0.00 equaled Cogent Biosciences'average media sentiment score. Company Overall Sentiment Calliditas Therapeutics AB (publ) Neutral Cogent Biosciences Neutral Which has more volatility & risk, CALT or UMRX? Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500. Comparatively, Cogent Biosciences has a beta of 3.93, indicating that its stock price is 293% more volatile than the S&P 500. SummaryCogent Biosciences beats Calliditas Therapeutics AB (publ) on 8 of the 11 factors compared between the two stocks. Get Cogent Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for UMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding UMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UMRX vs. The Competition Export to ExcelMetricCogent BiosciencesPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$321.92M$790.73M$5.54B$9.05BDividend YieldN/A4.84%5.24%4.02%P/E Ratio-9.971.3527.4320.23Price / Sales14.31226.97422.11118.64Price / CashN/A23.4436.8958.07Price / Book7.296.298.045.67Net Income-$31.83M-$27.73M$3.18B$249.13M Cogent Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UMRXCogent BiosciencesN/A$7.58+2.3%N/A-9.3%$321.92M$22.50M-9.9772CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180ZYMEZymeworks2.0055 of 5 stars$12.41-1.1%$21.00+69.2%+53.0%$863.45M$93.38M-8.27460Analyst ForecastCMRXChimerix0.6357 of 5 stars$8.54flat$8.53-0.1%N/A$801.09M$212K-9.0990CDMOAvid Bioservices0.7067 of 5 stars$12.50+0.1%$12.25-2.0%+62.3%$799.18M$139.91M-5.23320High Trading VolumeMENSJyong BiotechN/A$8.48-0.2%N/AN/A$646.23MN/A0.0031SBTXSilverback TherapeuticsN/A$17.45-4.1%N/A+81.7%$629.21MN/A-7.2183High Trading VolumeMBXMBX Biosciences3.1241 of 5 stars$11.61+1.8%$37.50+223.0%N/A$388.05MN/A0.0036RVNCRevance Therapeutics2.7812 of 5 stars$3.65flat$8.45+131.5%N/A$381.02M$234.04M-1.89500CKPTCheckpoint Therapeutics0.4872 of 5 stars$4.26flat$4.33+1.7%N/A$370.71M$41K-2.3210AVTEAerovate TherapeuticsN/A$9.99+8.7%N/A-81.2%$289.56MN/A-3.3420High Trading Volume Related Companies and Tools Related Companies CALT Alternatives ZYME Alternatives CMRX Alternatives CDMO Alternatives MENS Alternatives SBTX Alternatives MBX Alternatives RVNC Alternatives CKPT Alternatives AVTE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:UMRX) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cogent Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cogent Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
